Ariane J. Brown

TL;DR: A new mouse-adapted SARS-CoV-2 virus that captures multiple aspects of severe COVID-19 disease in standard laboratory mice is generated and characterized to provide a robust platform for studies of ALI and ARDS to evaluate vaccine and antiviral drug performance.

TL;DR: This mouse-adapted SARS-CoV-2 model demonstrates age-related disease pathogenesis and supports the clinical use of IFN lambda-1a treatment in human COVID-19 infections and shows that clinical candidate interferon (IFN) lambda- 1a can potently inhibit SARS's replication in primary human airway epithelial cells in vitro and both prophylactic and therapeutic administration diminished replication in mice.

TL;DR: The in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug ofGS-441524, the parent nucleoside of remdesivir, which targets the highly conserved virus RNA-dependent RNA polymerase of SARS-CoV-2 are demonstrated.

TL;DR: The potency of NHC/EIDD-2801 against multiple coronavirus, its therapeutic efficacy, and oral bioavailability in vivo, all highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.

TL;DR: Remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and supports its further clinical testing for treatment of COVID-19.